1621435-13-9

Basic information

• Product Name: tert-butyl 2-(((2S, 3R)-1, 3-bis (benzyloxy)-1-oxobutan-2-yl) carbamoyl)-2-(hydroxymethyl) pyrrolidine-1-carboxylate
• Synonyms: tert-butyl 2-(((2S, 3R)-1, 3-bis (benzyloxy)-1-oxobutan-2-yl) carbamoyl)-2-(hydroxymethyl) pyrrolidine-1-carboxylate
• CAS NO: 1621435-13-9
• Molecular Weight: 526.63
• Mol File: 1621435-13-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: tert-butyl 2-(((2S, 3R)-1, 3-bis (benzyloxy)-1-oxobutan-2-yl) carbamoyl)-2-(hydroxymethyl) pyrrolidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 2-(((2S, 3R)-1, 3-bis (benzyloxy)-1-oxobutan-2-yl) carbamoyl)-2-(hydroxymethyl) pyrrolidine-1-carboxylate(1621435-13-9)
• EPA Substance Registry System: tert-butyl 2-(((2S, 3R)-1, 3-bis (benzyloxy)-1-oxobutan-2-yl) carbamoyl)-2-(hydroxymethyl) pyrrolidine-1-carboxylate(1621435-13-9)

Safety Data

• Hazardous Substances Data: 1621435-13-9(Hazardous Substances Data)

Upstream product

• 1621435-12-8 1-(tert-butoxycarbonyl)-2-(hydroxymethyl)pyrrolidine-2-carboxylic acid 
• 42001-91-2 (2S,3R)-benzyl 2-amino-3-(benzyloxy)butanoate oxalate 
• 1621482-38-9 1-tert-butyl 2-ethyl 2-((benzyloxy)methyl)pyrrolidine-1,2-dicarboxylate 
• 135097-23-3 (2S)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester 
• 33305-75-8 L-proline ethyl ester monohydrochloride 
• 15260-10-3 N-Boc-O-benzyl-L-threonine 
• 1194030-71-1 2-((benzyloxy)methyl)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid 
• 1206898-37-4 rac-1-tert-butyl 2-methyl 2-[(benzyloxy)methyl]pyrrolidine-1,2-dicarboxylate 
• 59936-29-7 (S)-N-(tert-butoxycarbonyl)proline methyl ester 
• 147-85-3 L-proline 
• 67580-86-3 (2S,3R)-benzyl 2-amino-3-(benzyloxy)butanoate hydrochloride 
• 54276-70-9 N‐(tert‐butoxycarbonyl)‐O‐benzyl‐L‐threonine benzyl ester 

Downstream Products

• 1621435-56-0 (2S,3R)-3-hydroxy-2-(5-isobutyryl-1-oxo-2,5-diazaspiro[3.4]octan-2-yl)butanamide 
• 1621435-77-5 benzyl (2S,3R)-2-(5-acetyl-1-oxo-2,5-diazaspiro[3.4]octan-2-yl)-3-(benzyloxy)butanoate 
• 1621435-28-6 tert-butyl 2-((2S, 3R)-1, 3-bis (benzyloxy)-1-oxobutan-2-yl)-1-oxo-2, 5-diazaspiro [3.4] octane-5-carboxylate 
• 1621436-26-7 tert-butyl (R)-2-((2S,3R)-1,3-bis(benzyloxy)-1-oxobutan-2-yl)-1-oxo-2,5-diazaspiro [3.4]octane-5-carboxylate 
• 1621435-14-0 tert-butyl (S)-2-((2S,3R)-1,3-bis(benzyloxy)-1-oxobutan-2-yl)-1-oxo-2,5-diazaspiro[3.4]octane-5-carboxylate 
• 2012536-16-0 (2S,3R)-3-hydroxy-2-((R)-5-isobutyryl-1-oxo-2,5-diazaspiro[3.4]octan-2-yl)butanamide 
• 2012536-16-0 (2S,3R)-3-hydroxy-2-((S)-5-isobutyryl-1-oxo-2,5-diazaspiro[3.4]octan-2-yl)butanamide 

Relevant articles and documents

METHODS OF TREATING FIBROMYALGIA

Provided herein are methods of treating fibromyalgia, in a patient by administering to the patient an effective amount of NYX-2925 or a pharmaceutically acceptable salt thereof.

SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF

Disclosed are compounds having enhanced potency in the modulation of NMD A receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.